Our data show that the gut microbiome is altered in people with (long-standing) type 1 diabetes and is associated with glycemic control and diabetes-related complications. As a result of the cross-sectional design, the causality of these relationships remains to be determined (Diabetes Care)
Diabetes News
Tag: microbiome
The Gut Microbiome of Adults With Type 1 Diabetes and Its Association With the Host Glycemic Control
We identified a distinct gut microbial signature in adults with longstanding T1D and associations between microbial taxa, metabolic pathways, and glycemic control indices (Diabetes Care)
Metformin Affects Gut Microbiome Composition and Function and Circulating Short-Chain Fatty Acids: A Randomized Trial
Metformin, but not behavioral weight loss, impacted gut microbiota composition at 6 months and 12 months. Both metformin and behavioral weight loss altered circulating SCFAs at 6 months, including increasing acetate, which correlated with lower fasting insulin (Diabetes Care)
Gut microbiota changes after metabolic surgery in adult diabetic patients with mild obesity: a randomised controlled trial
This was the first RCT studying composite clinical, analytic, and microbiome changes in T2DM patients with class 1 obesity after RYGB versus standard medical therapy. The remarkable phenotypic improvement after surgery occurred concomitantly with changes in the gut microbiome, but at a lower level (Diabetology & Metabolic Syndrome)
Faecal microbiota transplantation halts progression of human new-onset type 1 diabetes in a randomised controlled trial
FMT halts decline in endogenous insulin production in recently diagnosed patients with T1D in 12 months after disease onset. Several microbiota-derived plasma metabolites and bacterial strains were linked to preserved residual beta cell function. This study provides insight into the role of the intestinal gut microbiome in T1D(BMC Gut)
Personalized Nutrition by Prediction of Glycemic Responses
Using personal and microbiome features enables accurate glucose response prediction (Cell)
MicroBiome Therapeutics Receives Positive Response From FDA For Use Of Expedited Regulatory Pathway For Diabetes Drug NM505
NM505 is a proprietary combination of an MBT microbiome modulator and metformin, the most widely prescribed first-line therapy worldwide for Type 2 diabetes. A recently-published, peer-reviewed proof-of-concept clinical study showed that NM505 improves the tolerability of metformin while further reducing blood glucose levels in patients with Type 2 diabetes
Glycosmedia is also available as an App: